ArticleHuman genomics and proteomics : HGP2010
Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate.
Article in Human genomics and proteomics : HGP, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis.Inflammatory bowel diseases · 2018Pooled it
- Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours.British journal of clinical pharmacology · 2020Article
- Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.Eye (London, England) · 2019Article
- Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate.Arthritis & rheumatology (Hoboken, N.J.) · 2014Article
- Clinically relevant pharmacogenomic testing in pediatric practice.Clinical pediatrics · 2014Article
- Personalised medicine in paediatrics: individualising treatment in children with rare neurological diseases.The EPMA journal · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although methotrexate is widely used in clinical practice there remains significant lack of understanding of its mechanisms of action and the factors that contribute to the variability in toxicity and response seen clinically. In addition to differences in drug administration, factors that affect pharmacokinetics and pharmacodynamics such as genetic variation may explain individual differences in drug biotransformation. However, the pediatric population has an additional factor to consider, namely the ontogeny of gene expression which may result in variation throughout growth and development. We review the current understanding of methotrexate biotransformation and the concept of ontogeny, with further discussion of how to implement a developmental pharmacogenomics approach in future studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.